1	2	3
11. *Isoxamine*		
(i) M/s. CIPLA	Tonnes	25.000
(ii) M/s. Dr. Reddy Labs.	,,	50.000

Statement-II

Demand Projection/Production (Tons.)

Name of the drug	1984-85		1985-86	
	Demand	Production	Demand	Production
1. Mebendazole	20.48	43.00*	33.01	
2. Terbutaline	0.37	0.29	0.40	
3. Salbutamol Sulphate	0.60	2.00	0.97	

*This includes demand for Thiabendazole also.

Formulations Based on Ranitidine HCL.

614. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to state:

(a) what were the maximum retail prices fixed for formulations based on Ranitidine HCL an Anti-ulcer drug for different packs and different strengths;

(b) whether it is a fact that certain companies are selling these formulations at much higher prices then approved by Government;

(c) if so, what are the names of those companies alongwith prices at which this medicine is being sold to consumer by them;

(d) whether it is also a fact that drug companies are selling the formulations based on imported bulk drugs after getting them produced from small scale units under their brand names despite the fact that these companies are licensed to produce bullt drug indigenously;

(e) if so, names of those companies alongwith them names of the formulations and their prices; and

(f) what steps have been taken to stop such activities which are against the consumer and country's interest?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAICHANDRA SINGH): (a) A maximum retail prices of Rs. 14.17 was fixed for 10's (150mg. tablets) of Unichem Labs. in January, 1987.

(b) and (c) No such instance has come to the notice of Government. However, the representation of M/s Indian Drugs Manufacturers' Association for treating this formulation under price decontrolled category is under examination.

(d) M/s. Glaxo Lab. (India) who was granted letter of intent for manufacture

of Ranitidine HCL is reportedly marke- small scale company named, M/s. Biotech ting Ranitidine tablets manufactured by a Pharma, Hyderabad.

(e) The details are given below:

Sr. No.	Name of the Formulation	Pack Size	Retail Price
1	Zenitec Tablets 150 mg/tab	10's	28.86
2	Do. 300 mg/tab	10's	55.65

(f) Government has recently announced some new policy measures to ensure abundant availability of drugs at reasonable prices and new Drug (Prices Control) Order incorporating these measures wolud be announced in due course.

Drugs manufacturing under New Drug Policy

615. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to state:

(a) whether his attention has been drawn to the news item which appeared in the Times of India of 6th January, 1987 captioned "Drug Policy faulted for bloated list";

(b) if so, whether it is a fact that three fourths of total formulations are non-essential and useless;

(c) whether it is also a fact that no measures has been proposed in the policy statement about discouragement of non-essential medicines;

(d) whether it is also a fact that statement propose price decontrol for non-essential and useless medicines;

(e) if so, whether it is also a fact that the production of non-essential and useless medicines exempted from price control under Drug Price Control Order 1979 went eight to ten times and essential medicines just the reverse; and

(f) what other steps are being proposed to control the production of non-essential medicines and encourage essential and useful medicines?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R.K. JAICHANDRA SINGH): (a) Yes, Sir.

(b) No, Sir.

(c) No, Sir.

(d) The new Drug Price Control Order has not yet been announced.

(e) No, Sir.

(f) Abundant availability, at reasonable prices of essential life saving and prophylactic medicines of good quality, is the corner stone of the new measures announced. New formulations based on drugs already approved for use in the country would not be allowed to be manufactured unless their therapeutic efficacy and rationality are adequately tested and proved.

Payment due from Drug Companies

616. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to state:

(a) whether Government's attention has been drawn to the news-item which appeared in the Economic Times of 28th December, 1986 captioned "Payment notices issued to five Drug Companies";

(b) if so whether it is a fact that Rs. 35 crores have been worked out as unintended benefit made by these companies;

(c) what is the exact amount due from each company;